Stamos Capital Partners’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$807K Sell
5,788
-1,498
-21% -$210K 0.13% 121
2025
Q4
$894K Buy
7,286
+2,566
+54% +$312K 0.14% 124
2025
Q3
$524K Sell
4,720
-2,963
-39% -$337K 0.1% 127
2025
Q2
$852K Buy
7,683
+59
+0.8% +$6.28K 0.15% 119
2025
Q1
$854K Sell
7,624
-5,826
-43% -$601K 0.22% 110
2024
Q4
$1.24M Sell
13,450
-19,510
-59% -$1.76M 0.29% 99
2024
Q3
$2.76M Sell
32,960
-10,350
-24% -$790K 0.65% 41
2024
Q2
$2.97M Buy
43,310
+6,750
+18% +$450K 0.63% 37
2024
Q1
$2.68M Buy
36,560
+5,960
+19% +$458K 0.61% 40
2023
Q4
$2.48M Sell
30,600
-14,710
-32% -$1.14M 0.67% 44
2023
Q3
$3.4M Buy
45,310
+870
+2% +$66.9K 0.76% 36
2023
Q2
$3.42M Buy
44,440
+7,020
+19% +$560K 0.8% 32
2023
Q1
$3.1M Buy
37,420
+5,670
+18% +$470K 0.8% 37
2022
Q4
$2.73M Sell
31,750
-15,900
-33% -$1.26M 0.86% 32
2022
Q3
$2.94M Buy
47,650
+26,450
+125% +$1.67M 0.75% 40
2022
Q2
$1.31M Hold
21,200
0.4% 51
2022
Q1
$1.26M Buy
+21,200
New +$1.36M 0.42% 44
2021
Q1
Sell
-50,700
Closed -$2.95M 48
2020
Q4
$2.95M Buy
+50,700
New +$3.06M 1.26% 27
2020
Q2
Sell
-13,454
Closed -$1.01M 72
2020
Q1
$1.01M Buy
+13,454
New +$930K 0.53% 58
2019
Q3
Sell
-3,600
Closed -$244K 47
2019
Q2
$244K Buy
+3,600
New +$237K 0.24% 50

Other funds holding GILD

Stamos Capital Partners's GILD Position: Q1 2026 in Review

Stamos Capital Partners reduced its Gilead Sciences (GILD) stake by 21% in Q1 2026, selling an estimated $210K and leaving 5,788 shares worth $807K. The position accounts for 0.13% of the portfolio, ranked #121.

Stamos Capital Partners first reported a position in GILD in Q2 2019 and has held it in 20 quarters since. The position peaked at $3.42M in Q2 2023. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Stamos Capital Partners held 5,788 shares of Gilead Sciences worth $807K as of Q1 2026.
  • Stamos Capital Partners sold 1,498 Gilead Sciences shares in Q1 2026, an estimated $210K.
  • Gilead Sciences made up 0.13% of Stamos Capital Partners's portfolio in Q1 2026, its #121 holding.
  • Stamos Capital Partners first reported a position in Gilead Sciences in Q2 2019 and has held it in 20 quarters since.
  • Stamos Capital Partners's Gilead Sciences position peaked at $3.42M in Q2 2023.
  • 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Stamos Capital Partners's 13F filing for Q1 2026, filed 14 May 2026.